Search

Search results

[Translate to English:]

The US company Immusoft has dosed the first subject with its investigational engineered B cell therapy, ISP-001, in a human Phase I clinical trial of mucopolysaccharidosis type I (MPS I).

[Translate to English:]

The EU-funded AiChemist project aims to provide advanced AI approaches with increased explainability and broad applicability. It brings together key players from academia and industry and includes a structured training program for AI specialists.

[Translate to English:]

‘Valuable insights, trusting atmosphere and great people’ was how a participant summed up her experience of the two-day workshop hosted by Ascenion exclusively for colleagues from its partner institutes, universities and clinics.

 

[Translate to English:]

The partners have initiated a phase I trial to evaluate LuCaFab (ITM-31), a radiolabelled a-CA XII antibody Fab fragment, for the treatment of glioblastoma. The goal is to eradicate residual tumour cells following surgery to reduce the risk of relapse.

Ascenion is looking forward to a reunion with industry decision makers, venture capitalists, academic inventors and entrepreneurs. Eight from a total of 56 projects to be featured originate from Ascenion’s academic partners.

TANGO Therapeutics will employ two CRISPR technologies invented by Ulrich Elling at IMBA and in part by Krzysztof Chylinski at VBCF to discover genes involved in tumourigenesis and immune evasion as targets for next-generation therapies.

Supported by Ascenion, Felix Krenzien and his team at Charité – Universitätsmedizin Berlin attracted the grant from the Else Kröner-Fresenius-Stiftung (EKFS) to translate their new approach for quantifying extracellular NAD+ into medical practice.

[Translate to English:]

Pharma-backed incubator INCATE selected the HZI start-up project Myxobiotics as one of the first start-ups to get support. Myxobiotics develops a new class of antibiotics against Acinetobacter baumannii, which causes severe, difficult-to-treat respiratory infections.

Supported by Ascenion, Matthias Bruhn and his team at TWINCORE - Centre for Experimental and Clinicial Infection Research have attracted EUR 97,000 to explore the commercial feasibility of their MEMUMAB project. The goal is to provide therapeutic antibodies against infectious diseases such as COVID-19.

The German Federal Ministry of Education and Research (BMBF) is providing EUR 6.5 million in funding for 10 selected research projects targeting long-term symptoms of COVID-19. Ascenion’s partner institutes are making significant contributions to three of these projects.

The method, SARSeq (Saliva Analysis by RNA sequencing), enables highly sensitive, massively-parallel and cost-effective testing for SARS-CoV-2. Ascenion has supported its patent protection and licencing for commercial use in China.

The HIOH pursues an integrative approach to understanding the emergence of new pathogens and developing suitable intervention mechanisms. Ascenion is its technology transfer partner.

 

[Translate to English:]

Scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius Maximilian University (JMU) in Würzburg have paved the way for a new diagnostic platform that enables the detection of multiple markers in one single test.

The current COVID-19 pandemic has drastically made us aware of how inadequate the present precautions are against infections transmitted by droplets…

Technology sneak peek from Ascenion: Seven breakthrough life-science inventions

[Translate to English:]

Heidelberg Pharma AG is allowed to initiate a Phase I/IIa clinical study in the US to evaluate the dosing, safety and anti-tumour efficacy of its lead candidate HDP-101 in multiple myeloma.

[Translate to English:]

Ascenion, technology transfer partner of Hannover Medical School (MHH), has supported the conclusion of a collaboration and licence agreement between MHH and Novo Nordisk.

[Translate to English:]

An innovative approach to combat infections caused by Staphylococcus aureus will receive funding of initially 1.33 million USD plus an additional 7.44 million USD, depending on project progress. It is jointly developed by the HZI and the LDC.

[Translate to English:]

Ascenion will support eight members and four partners of the Innovative Training Network (ITN) ‘SMABEYOND’ in all aspects relating to the intellectual property and potential commercialization of their work.

The TransferAllianz proposes 5 measures to leverage the innovation potential of academic research and drive sustainable economic recovery following the corona crisis.

[Translate to English:]

Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.

[Translate to English:]

Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.

A research team at the German Center for Neurodegenerative Diseases (DZNE) has received the ‘Hugo Junkers Award for Research and Innovation from Saxony-Anhalt 2019’.

Ascenion has supported the 20 parties of the European LifeTime research consortium in agreeing the legal framework for their scientific cooperation.

Ascenion GmbH, technology transfer partner of the Max Delbrück Center for Molecular Medicine (MDC), has supported the conclusion of an agreement between the MDC and Fate Therapeutics, Inc.

Should public research institutes and universities receive equity in start-ups founded to commercialize their intellectual property? And if so, how…

This year’s innovation prize from the Metropolregion Mitteldeutschland goes to a team that has brought a novel anti-tuberculosis compound all the way…

The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with…

Gramibactin is an iron-binding molecule of the siderophore family. It occurs naturally in certain plant-associated bacteria where it helps secure the…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a licence…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a…

Ascenion Negotiated Additional Licence Agreement between Helmholtz Zentrum München and Medigene

9 January 2019, Munich – The Helmholtz Zentrum…

Agreement with Max Delbrück Center Provides Access to Broad Intellectual Property Portfolio of Unique Humanized Antibody Fragments and Antigen-Binding…

This year’s technology transfer award from Braunschweig’s Chamber of Industry and Commerce goes to scientists at the Helmholtz Centre for Infection…

Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment…

Ascenion’s partner institute, the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI), has joined forces with the…

 

Shire’s VEYVONDI received EU market authorization for the treatment of bleeding events and the prevention or treatment of surgical bleeding in…

Ascenion has negotiated a licence agreement between Medical School Hannover (MHH) and its spin-off Cardior Pharmaceuticals providing the company with…

Ascenion, the knowledge and technology transfer partner of the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), has negotiated an agreement with Roche…

The U.S. Food and Drug Administration (FDA) has extended the scope of Shire’s VONVENDI to include perioperative management of bleeding in adults with…

Making cancer surgery more precise

23 October 2017, Munich – SurgVision BV, a spin-off from the Helmholtz Zentrum München, has been acquired by…

9 October 2017, Munich – Last week Ascenion GmbH and the Medical University of Innsbruck launched their cooperation with a joint kick-off event. The…

Three further research institutes have decided to enter into partnership with Ascenion in recent months. This brings the number of long-term partner…

Unique RNA-based approach for the treatment of heart diseases

11 May 2017, Munich – Cardior Pharmaceuticals has completed a EUR 15 million Series A…

A consortium of nine partners from five European countries, led by the Helmholtz Zentrum München, will work together with a transdisciplinary approach…

Heidelberg Pharma, a subsidiary of Wilex AG, and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) have signed a…

LentiBOOSTTM, an innovative gene therapy adjuvant, has got the green light from the FDA for use in a Phase III clinical trial. The technology, which…

Tubingen (Germany), January 05, 2017 – HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today…

Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I…

19 September 2016, Munich – Ascenion GmbH, the technology transfer partner of the Max Delbrück Center for Molecular Medicine in the Helmholtz…

For the first time, a German team has won the world’s biggest life-science start-up competition. Captain T Cell, founded by Dr Felix Lorenz and…

Cancer-fighting gene therapy

A ground-breaking approach to the therapy of HIV infection has been published in the current issue of Nature Biotechnology: a designer recombinase…

Flexible funds from technology transfer

21 December 2015, Berlin and Munich - ‘VONVENDI [von Willebrand factor (Recombinant)]’, the new drug from Baxalta Incorporated, a global…

The US biotech company Amgen announced at the end of November that its cancer therapy BLINCYTO® has been approved by the European Commission for the…

From 40 submitted projects – all excellent, according to the jury – five have now emerged as winners. These were chosen as having the potential to…

Ascenion’s portfolio company OMEICOS, a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, has received further funding of…

Ascenion takes equity in the MHH start-up Zellkraftwerk

BigChem GmbH was founded this October to commercialize validated IT products and services developed at the Helmholtz Zentrum München. The research was…

The negotiation of a licensing and cooperation agreement between Formula Pharmaceuticals and the Helmholtz Association’s Max Delbrück Center for…